methyl-octyl-amine; hydrochloride | 190582-28-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: methyl-octyl-amine; hydrochloride
• 英文别名: octylmethylammonium chloride；N-Methyloctan-1-amine--hydrogen chloride (1/1)；N-methyloctan-1-amine;hydrochloride
• CAS: 190582-28-6
• 化学式: C₉H₂₁N*ClH
• 分子量: 179.733
• InChiKey: LPHLNZHFRMZONI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.46
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  16.6
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  methyl-octyl-amine; hydrochloride 在 phosphorus yl chloride 、 xylene 、 苯 作用下， 生成 diphosphoric acid tris-dimethylamide-(methyl-octyl-amide)
  参考文献：
  名称：

  Higher Aliphatic Alkylheptamethylpyrophosphoramides

  摘要：

  DOI：

  10.1021/ja01627a089
• 作为试剂：
  描述：

  7-(trifluoromethyl)-1H-pyrrolo[1,2-c][1,3]thiazole 在 sodium tungstate (VI) dihydrate 、 苯膦酸 、 双氧水 、 methyl-octyl-amine; hydrochloride 作用下， 以 甲醇 、 水 、 乙酸乙酯 为溶剂， 以90%的产率得到2-oxo-7-trifluoromethyl-1H,3H-pyrrolo[1,2-c]thiazole
  参考文献：
  名称：

  通过非经典杂环稠合[ c ]噻唑的环加成反应实现氮桥杂环

  摘要：

  探索了非经典杂环稠合[ c ]噻唑的[4π+2π]环加成反应，从而合成了一系列新型的氮桥联双，三和四环杂环化合物，即吡唑并[1,5- a] ]吡啶，噻唑并[2,3,4- cd ]吡咯烷酮和吲哚嗪。首次分离出一种非经典的吡咯并[1,2- c ]噻唑，并通过X射线晶体学确定其结构。

  DOI：

  10.1016/j.tet.2011.08.001

文献信息

• MATERIAL FOR FORMING ORGANIC FILM, METHOD FOR FORMING ORGANIC FILM, PATTERNING PROCESS, AND COMPOUND
  申请人：SHIN-ETSU CHEMICAL CO., LTD.

  公开号：US20210286266A1

  公开（公告）日：2021-09-16

  The present invention is a material for forming an organic film, including: a compound shown by the following general formula (1); and an organic solvent, where in the general formula (1), X represents an organic group with a valency of “n” having 2 to 50 carbon atoms or an oxygen atom, “n” represents an integer of 1 to 10 , and R 1 independently represents any of the following general formulae (2), where in the general formulae (2), broken lines represent attachment points to X, and Q 1 represents a monovalent organic group containing a carbonyl group, at least a part of which is a group shown by the following general formulae (3), where in the general formulae (3), broken lines represent attachment points, X 1 represents a single bond or a divalent organic group having 1 to 20 carbon atoms optionally having a substituent when the organic group has an aromatic ring, R 2 represents a hydrogen atom, a methyl group, an ethyl group, or a phenyl group, and ** represents an attachment point. An object of the present invention is to provide a material for forming an organic film for forming an organic film having dry etching resistance, and also having high filling and planarizing properties and adhesion to a substrate.

  本发明是一种用于形成有机薄膜的材料，包括：由以下通用式（1）所示的化合物；和有机溶剂，在通用式（1）中，X代表具有2至50个碳原子或一个氧原子的价为“n”的有机基团，“n”表示1到10的整数，R1独立地表示以下通用式（2）中的任何一种，其中在通用式（2）中，虚线表示连接点到X，Q1表示含有羰基的一价有机基团，其中至少部分是以下通用式（3）所示的基团，其中在通用式（3）中，虚线表示连接点，X1表示单键或具有1到20个碳原子的二价有机基团，在有机基团具有芳香环时可选地具有取代基，R2表示氢原子、甲基基团、乙基基团或苯基团，**表示连接点。本发明的目的是提供一种用于形成具有干法刻蚀抗性的有机薄膜的材料，同时具有高填充和平整化性能以及对基底的粘附性。
• [EN] SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES<br/>[FR] PYRROLIDINES SUBSTITUÉES COMME INHIBITEURS DU FACTEUR XIA POUR LE TRAITEMENT DE MALADIES THROMBOEMBOLIQUES
  申请人：ONO PHARMACEUTICAL CO

  公开号：WO2013174937A1

  公开（公告）日：2013-11-28

  The present invention provides compounds of the general formula (I), their salts and N- oxides, and solvates and prodrugs thereof (wherein the substituents are as defined in the description). The compounds of the general formula (I) are inhibitors of factor XIa, and are useful in the prevention of and/or therapy for thromboembolic diseases.

  本发明提供了一般式(I)的化合物，以及它们的盐和N-氧化物、溶剂合物和前药（其中取代基如描述中定义）。一般式(I)的化合物是XIa因子的抑制剂，对预防和/或治疗血栓栓塞性疾病有用。
• [EN] METHOD OF MANUFACTURING AN ORGANOALKOXYSILANE HAVING ESTER-FUNCTIONAL GROUPS<br/>[FR] PROCÉDÉ DE FABRICATION D'UN ORGANOALKOXYSILANE AYANT DES GROUPES FONCTIONNELS ESTER
  申请人：DOW CORNING TORAY CO LTD

  公开号：WO2005103061A1

  公开（公告）日：2005-11-03

  A method of manufacturing an organoalkoxysilane that contains ester-functional groups comprising the step of causing a reaction between (a) an alkali-metal salt of a carboxylic acid and (b) an organoalkoxysilane that contains halogen-substituted organic groups (c) in the presence of a phase-transfer catalyst.

  一种制造含酯功能基团的有机烷氧基硅烷的方法，包括引发（a）羧酸的碱金属盐和（b）含有卤素取代有机基团的有机烷氧基硅烷之间的反应（c），在相转移催化剂的存在下。
• Stilbene derivatives and pharmaceutical compositions containing them
  申请人：Ajinomoto Co., Ltd.

  公开号：US05525632A1

  公开（公告）日：1996-06-11

  A stilbene derivative of the following general formula (I) or a pharmaceutically acceptable acid addition salt thereof have low toxicity, but are water soluble and effective as carcinostatics: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3, which may be the same or different, each represent an alkyl group having 1 to 3 carbon atoms; X represents a hydrogen atom or a nitrile group; Y represents an alkyloxy group having 1 to 3 carbon atoms, an alkyl group having 1 to 6 carbon atoms or a halogen atom.

  以下一般式（I）的一种stilbene衍生物或其药学上可接受的酸盐具有低毒性，但水溶性强，且作为抗癌药物具有有效性：其中R.sup.1、R.sup.2和R.sup.3，可以相同也可以不同，每个代表具有1至3个碳原子的烷基基团；X代表氢原子或腈基团；Y代表具有1至3个碳原子的烷氧基团，具有1至6个碳原子的烷基基团或卤素原子。
• Pharmaceutical composition for treatment of disease due to vascular constriction or vasodilation
  申请人：Nakade Shinij

  公开号：US20060148844A1

  公开（公告）日：2006-07-06

  A therapeutic and/or preventing agent for a disease due to vascular constriction or vasodilation comprising a EDG-5 modulator. Since EDG-5 modulator specifically binds EDG-5 and shows antagonistic or agonistic action, EDG-5 antagonist is useful for treating and/or preventing for a disease due to vascular constriction, for example, cerebrovascular spasmodic disorder after subarachnoid hemorrhage or stroke, cardiovasucular spasmodic disorder, hypertension, renal disease, cardiac infarction, cardiac angina, arrhythmia, facilitation of the portal blood pressure involved in liver cirrhosis, varicosity involved in liver cirrhosis and the like, or EDG-5 agonist is useful for treating and/or preventing for a disease due to vasodilation of blood vessels, for example, chronic headache (such as migraine, tension-type headache, mixed-type headache thereof, or migrainous neuralgia), haemorrhoid, congestive disorder and the like.

  一种治疗和/或预防由血管收缩或扩张引起的疾病的药物，包括EDG-5调节剂。由于EDG-5调节剂专门结合EDG-5并显示拮抗或激动作用，因此EDG-5拮抗剂可用于治疗和/或预防由血管收缩引起的疾病，例如蛛网膜下出血或中风后的脑血管痉挛性障碍，心血管痉挛性障碍，高血压，肾脏疾病，心肌梗死，心绞痛，心律失常，促进涉及肝硬化的门静脉血压，涉及肝硬化的静脉曲张等，或EDG-5激动剂可用于治疗和/或预防由血管扩张引起的疾病，例如慢性头痛（如偏头痛，紧张型头痛，混合型头痛或偏头痛性神经痛），痔疮，充血性疾病等。